Form 4: J&J VP Corporate Controller's PSU Vesting

Johnson & Johnson's VP Corporate Controller, Robert J. Decker, reported the vesting of 2,741 Performance Share Units.

Summary

• Robert J. Decker, VP Corporate Controller of Johnson & Johnson (JNJ), reported the vesting of 2,741 Performance Share Units (PSUs).
• These PSUs were originally awarded on February 13, 2023, under the company's Long-Term Incentive Plan.
• The vesting occurred on February 9, 2026, following the certification of performance conditions set forth in the award agreement.
• Each PSU converts into one share of JNJ Common Stock upon vesting.
• Following this transaction, Robert J. Decker beneficially owns 2,741 derivative securities (PSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies the achievement of performance targets tied to executive compensation, reflecting positively on the company's operational execution during the performance period.

Positives

• The vesting of Performance Share Units indicates that the company met the performance conditions set forth in the award agreement, which is a positive sign for operational execution during the performance period.
• The award aligns management incentives with long-term shareholder value creation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on an executive's equity transaction.

Industry Context

StockSavvy.ai notes that the vesting of executive performance share units is a standard component of long-term incentive plans across large-cap pharmaceutical and consumer health companies. This practice aims to align executive compensation with company performance over multi-year periods, a common strategy to retain talent and drive strategic objectives within the competitive healthcare sector.

Comparison to Industry Standards

• The use of Performance Share Units (PSUs) is a common executive compensation practice among S&P 500 companies, particularly in the healthcare and consumer goods sectors, similar to practices at Pfizer, Procter & Gamble, and Merck.
• The structure, where PSUs convert to common stock upon meeting performance conditions, aligns with best practices for linking executive incentives to shareholder value, mirroring programs seen at companies like Abbott Laboratories and Medtronic.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates that performance targets were met, which could be viewed positively as it suggests successful execution of company strategy during the award period.
• Employees (specifically Robert J. Decker): The vesting represents a realization of compensation tied to performance, directly benefiting the executive.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (vesting of performance share units) and does not contain information that would fundamentally alter the investment thesis for Johnson & Johnson. It confirms the company met performance targets for the award period, which is a minor positive, but not significant enough to warrant a change in investment recommendation based solely on this filing.

Keywords

Johnson & Johnson, JNJ, Form 4, Insider Trading, Performance Share Units, PSU, Executive Compensation, Robert J. Decker, Long-Term Incentive Plan, Stock Vesting